FEATURE ARTICLES
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
- How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
- The EU Overhauls Pharma Laws: What You Need To Know
- Modulus Brings Home Top Award At 2026 FOYAs
- Designing Pharma Facilities For Change, Not Just Capacity
- September 2026 — CDMO Opportunities And Threats Report
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
- Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-2166352840-scientists-in-lab-with-computer-screen]( "AI Enabled Pharmaceutical Cocrystal Screening")
AI Enabled Pharmaceutical Cocrystal ScreeningCocrystal candidate screening is resource-intensive and prone to gaps. This paper examines how AI-based modeling, trained on more than 20,000 data points, can sharpen candidate prioritization without sacrificing scientific rigor.
-
The Open Standard For Plug-And-Produce4/14/2026
Take a look at how standardized, modular production simplifies line integration, reduces engineering effort, and enables faster changeovers. Ideal for teams seeking flexible manufacturing models.
-
SMB Technology: Optimizing API Purification6/13/2025
Explore how Simulated Moving Bed (SMB) technology can enhance API production while overcoming common misconceptions about chromatographic purification.
-
The Analytical Advantage Across The Development Lifecycle5/7/2026
Integrated, regulatory‑ready analytics help accelerate development, strengthen submissions, and ensure consistent product quality throughout the pharmaceutical lifecycle.
-
Leveraging 3 Distinct Resins To Provide Effective Impurity Removal For mAbs And Novel Antibody Derivatives11/3/2025
Due to the complexity of bispecifics, Fc-fusion proteins, and Fab fragments, their manufacturing poses added purification challenges and requires a robust toolkit of purification techniques.
-
SEDDS: Improving Oral Bioavailability Of Poorly Soluble Compounds8/20/2026
Nearly 90% of marketed drugs have poor water solubility. Learn how self-emulsifying drug delivery systems (SEDDS) resolve oral bioavailability failures across BCS Class II and IV compounds.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Raise Your Standards With Downflow Booth Airflow Containment
- API Solubility And Dissolution Enhancement Via Formulation
- Validation Provider Shortens The Path To Equipment Qualification
- Ultra Low Temperature Packaging Solutions
- Practical Considerations For Aseptic Gowning In Contamination Control Strategies (CCS)
NEWSLETTER ARCHIVE
- 11.03.26 -- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- 11.03.26 -- Where Speed Is Lost: Fixing Handoffs In BioPharma Operations
- 11.02.26 -- What's Next in Pharmaceutical Packaging?
- 11.02.26 -- Is Your Pharma Factory Ready For What's Next?
- 10.31.26 -- Aseptic Contract Manufacturing Services
- Modulus Brings Home Top Award At 2026 FOYAs
- Designing Pharma Facilities For Change, Not Just Capacity
- Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up
- Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma
- Capturing Tablet Disintegration for Improved OSD Development
NEW FOR OUR READERS
INDUSTRY NEWS
-
![white coupon banner, great topic-GettyImages-2271702407]( "Let Your Voice Help Shape Pharma Manufacturing")
Let Your Voice Help Shape Pharma ManufacturingPharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.
-
![rating service, satisfaction-GettyImages-2221603596]( "ISPE Announces 2026 FOYA Winners")
ISPE Announces 2026 FOYA WinnersThese awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
EDITORIAL COLLECTIONS
Our curated Editorial Collections bring expert insights together in one place, offering practical perspectives and actionable guidance to help you navigate complex decisions and improve performance.
More Editorial CollectionsSUPPLIER NEWS
-
Lonza Signs Agreement To Acquire US CDMO Network From Merck KGaA, Darmstadt, Germany, And Significantly Expands Its US Presence11/3/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today that it has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck KGaA, Darmstadt, Germany at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs.
-
Bracco To Build New Injectable Drug Manufacturing Facility In North Carolina11/2/2026
Bracco, a global leader in diagnostic imaging, today announced plans to invest $230 million to establish its first U.S. manufacturing facility for injectable contrast media in Sanford, North Carolina. Expected to create 200 jobs, the investment marks a significant milestone in Bracco's global manufacturing strategy, expanding production capacity and strengthening supply chain resilience in the United States, the company's largest market.
-
Lonza Further Expands Bioconjugation Manufacturing To Support Growing ADC Demand10/29/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today the further expansion of its integrated bioconjugation manufacturing offering. Lonza is combining the flexibility of mid-scale bioconjugation manufacturing with its previously announced large-scale bioconjugation expansion in Visp (CH), which will now include three multiproduct suites. Together, these capabilities will offer customers a scalable manufacturing pathway from clinical development through commercial supply for antibody-drug conjugates (ADCs) and other bioconjugates.
-
ROSS Portable High Shear Mixing System10/29/2026
-
Ardena Launches Online Biomarker Catalogue: 228 Markers, One Quote Request10/29/2026
Ardena has launched a searchable Biomarker Catalogue on its website, giving sponsors a faster route from biomarker selection to a bioanalysis quote.
